Abstract
Background: Both human leukocyte antigen (HLA) class I and programmed death-ligand 1 (PD-L1) molecules are known to play important roles in cancer immunity. In this study, we evaluated HLA class I expression in resected adenocarcinoma of the lung, and investigated its prognostic impact in correlation with PD-L1 expression. Methods: HLA class I and PD-L1 expression was evaluated by immunohistochemistry in a total of 403 resected lung adenocarcinomas using tissue microarray. Correlations between the expression of HLA class I/PD-L1 and clinicopathologic features and prognostic significance were analyzed. Results: HLA class I expression was reduced in 91.6% of adenocarcinoma, and more frequently reduced in patients with younger age, absence of vascular invasion, and low pathologic stage (p = .033, p = .007, and p = .012, respectively). Positive PD-L1 expression in tumor cells was 16.1% (1% cut-off), and associated with poor differentiation, presence of vascular invasion and nodal metastasis (p
Author supplied keywords
Cite
CITATION STYLE
Han, Y. B., Kwon, H. J., Park, S. Y., Kim, E. S., Kim, H., & Chung, J. H. (2019). Human leukocyte antigen class I and programmed death-ligand 1 coexpression is an independent poor prognostic factor in adenocarcinoma of the lung. Journal of Pathology and Translational Medicine, 53(2), 86–93. https://doi.org/10.4132/jptm.2018.12.26
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.